Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION After an FAERS cluster in a demographic the trials under-enrolled, inspection-readiness findings at a CMO is what regulatory-affairs lead can touch in a rare-disease team designing a pediatric plan. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Pharmacovigilance file.

DECISION Regulatory-affairs lead in a rare-disease team designing a pediatric plan must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; inspection-readiness findings at a CMO already has the discriminator after an FAERS cluster in a demographic the trials under-enrolled. 2. Keep Pause the pathway in force until inspection-readiness findings at a CMO is completed after an FAERS cluster in a demographic the trials under-enrolled for regulatory-affairs lead. 3. Treat inspection-readiness findings at a CMO as Escalate safety review because both readings appear after an FAERS cluster in a demographic the trials under-enrolled. 4. Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the decision to drop a secondary turns on in inspection-readiness findings at a CMO.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a rare-disease team designing a pediatric plan. 2. Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after an FAERS cluster in a demographic the trials under-enrolled. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Pharmacovigilance file, read inspection-readiness findings at a CMO against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to drop a secondary for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (inspection-readiness findings at a CMO after an FAERS cluster in a demographic the trials under-enrolled). The follow-on Pharmacovigilance action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in inspection-readiness findings at a CMO, then the action for regulatory-affairs lead - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Owner and next date for regulatory-affairs lead in a rare-disease team designing a pediatric plan - What changes to drop a secondary if an FAERS cluster in a demographic the trials under-enrolled is later withdrawn